CD19 CAR-T Cells for Leukemia and Lymphoma
(MULTIPRAT Trial)
Trial Summary
Will I have to stop taking my current medications?
The trial requires that you stop taking other investigational antiviral or antitumor therapies for one month before joining. If you are currently on corticosteroids for graft versus host disease, you cannot participate.
What data supports the effectiveness of the treatment CD19 CAR-T Cells for Leukemia and Lymphoma?
CD19 CAR-T cells have shown remarkable results, inducing complete remissions in up to 90% of patients with relapsed or chemotherapy-resistant B-cell acute lymphoblastic leukemia, a type of blood cancer. This is a significant improvement compared to the 30% response rate expected with traditional chemotherapy.12345
Is CD19 CAR-T cell therapy safe for humans?
CD19 CAR-T cell therapy can cause serious side effects like cytokine release syndrome (a severe immune reaction) and neurological issues, but these are generally manageable with supportive care. Some patients may experience infections or other complications, but ongoing research is focused on improving safety measures.26789
How is the CD19 CAR-T cell treatment different from other treatments for leukemia and lymphoma?
CD19 CAR-T cell treatment is unique because it uses genetically modified T cells to specifically target and attack cancer cells expressing the CD19 protein, which is common in B-cell leukemias and lymphomas. This approach can lead to high remission rates in patients who do not respond to traditional chemotherapy, making it a promising option for difficult-to-treat cases.123410
What is the purpose of this trial?
Subjects are having a bone marrow or SCT for either a type of cancer of the blood called Leukemia or a cancer of the lymph nodes called non- Hodgkin's Lymphoma. Although a transplant can cure leukemia or lymphoma, some people will relapse. In those who relapse, current treatment cures only a very small percentage. Although giving patients a dose of donor immune cells before relapse can prevent relapse of the leukemia or lymphoma, DLI can also cause a serious complication called graft versus host disease (GVHD). This is a gene transfer research study using special immune cells which are specific for these cancer cells.The body has different ways of fighting infection and disease. This study combines 2 of those ways, antibodies and T cells. T cells (CTLs or cytotoxic T cells) are infection-fighting blood cells that can kill cells, including tumor cells. Antibodies and T cells have been used to treat patients with cancers; they have shown promise, but haven't been strong enough to cure most patients.The antibody used in this study is called anti-CD19. This antibody sticks to leukemia cells because of a substance on the outside of these cells called CD19. For this study, the anti-CD19 antibody has been changed so that instead of floating free in the blood it is now joined to T cells. When an antibody is joined to a T cell in this way it's called a chimeric receptor.In the laboratory, investigators found that T cells that are trained to recognize common viruses can stay in the blood stream for many years. By joining the anti-CD19 antibody to CTLs that recognize viruses, they believe that they will also be able to make a cell that can last a long time in the body, provide protection from viruses, and recognize and kill leukemia. The CTLs which we will join the anti-CD19 antibody to attack 3 viruses (trivirus-specific CTLs), CMV, EBV, and adenovirus.Studies have shown that trivirus-specific CTLs grown from the stem cell donor can be given safely to transplant recipients and can stop these viruses from causing severe infections. These CD19 chimeric receptor trivirus specific T cells are an investigational product not approved by the FDA.The purpose of this study is to find the biggest dose of chimeric T cells that is safe, to assess the side effects, to see how long the T cells last and to evaluate whether this therapy might help prevent infections and relapse in people with CD19+ leukemia or lymphoma having a SCT.
Research Team
Carlos Ramos, MD
Principal Investigator
Baylor College of Medicine
Eligibility Criteria
This trial is for patients of any age and sex with CD19+ B-ALL or B-CLL/NHL undergoing a bone marrow transplant. They must have a life expectancy of at least 6 weeks, be able to consent, and use effective birth control post-treatment. Excluded are those with severe allergies to murine proteins, active GVHD above grade II, pregnancy, lactation, or severe infections.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single dose of CD19 chimeric receptor trivirus specific T cells post-HSCT, with potential for up to 6 additional doses if stable disease or partial response is observed
Follow-up
Participants are monitored for safety, effectiveness, and long-term side effects of gene transfer
Treatment Details
Interventions
- CD19CAR/virus specific T cells
Find a Clinic Near You
Who Is Running the Clinical Trial?
Baylor College of Medicine
Lead Sponsor
Center for Cell and Gene Therapy, Baylor College of Medicine
Collaborator
The Methodist Hospital Research Institute
Collaborator